Do analysts prefer HZD or 4BB?

4basebio has a consensus target price of GBX 1,400, indicating a potential upside of 188.66%. Given 4basebio's stronger consensus rating and higher probable upside, analysts plainly believe 4basebio is more favorable than Horizon Discovery Group plc (HZD.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Horizon Discovery Group plc (HZD.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is HZD or 4BB more profitable?

Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat 4basebio's return on equity. Company Net Margins Return on Equity Return on Assets Horizon Discovery Group plc (HZD.L) N/A N/A N/A 4basebio N/A -231.29% -54.30%

Which has preferable valuation and earnings, 4BB or AVCT?

4basebio has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than 4basebio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 4basebio £1.69M 44.36 -£9.84M -£109.00 N/A Avacta Group £113K 2,778.12 -£30.08M -£9.66 N/A

Is 4BB or AVCT more profitable?

4basebio has a net margin of 0.00% compared to Avacta Group's net margin of -33,961.06%. 4basebio's return on equity of -231.29% beat Avacta Group's return on equity. Company Net Margins Return on Equity Return on Assets 4basebio N/A -231.29% -54.30% Avacta Group -33,961.06% -2,929.47% -21.80%

Does the media refer more to 4BB or AVCT?

In the previous week, 4basebio and 4basebio both had 1 articles in the media. 4basebio's average media sentiment score of 0.75 beat Avacta Group's score of 0.67 indicating that 4basebio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4basebio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avacta Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PRTC or 4BB more profitable?

4basebio has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. PureTech Health's return on equity of -31.98% beat 4basebio's return on equity. Company Net Margins Return on Equity Return on Assets PureTech Health -2,355.32% -31.98% -13.39% 4basebio N/A -231.29% -54.30%

Does the media favor PRTC or 4BB?

In the previous week, PureTech Health and PureTech Health both had 1 articles in the media. PureTech Health's average media sentiment score of 1.11 beat 4basebio's score of 0.75 indicating that PureTech Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4basebio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend 4BB or ARIX?

4basebio currently has a consensus target price of GBX 1,400, suggesting a potential upside of 188.66%. Given 4basebio's stronger consensus rating and higher possible upside, equities research analysts plainly believe 4basebio is more favorable than Arix Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Arix Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer CIR or 4BB?

4basebio has a consensus price target of GBX 1,400, suggesting a potential upside of 188.66%. Given 4basebio's stronger consensus rating and higher probable upside, analysts plainly believe 4basebio is more favorable than Circassia Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Circassia Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is CIR or 4BB more profitable?

Circassia Group's return on equity of 0.00% beat 4basebio's return on equity. Company Net Margins Return on Equity Return on Assets Circassia Group N/A N/A N/A 4basebio N/A -231.29% -54.30%

4basebio (4BB) Competitors

GBX 485 +20.00 (+4.30%)

As of 08/21/2026 11:37 AM Eastern

Compare

4BB vs. HZD, AVCT, PRTC, ARIX, and CIR

Should you buy 4basebio stock or one of its competitors? 4basebio's main competitors and comparable companies include Horizon Discovery Group plc (HZD.L) (HZD), Avacta Group (AVCT), PureTech Health (PRTC), Arix Bioscience (ARIX), and Circassia Group (CIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does 4basebio compare to Horizon Discovery Group plc (HZD.L)?

Horizon Discovery Group plc (HZD.L) (LON:HZD) and 4basebio (LON:4BB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

0.9% of 4basebio shares are held by institutional investors. 12.1% of 4basebio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A
4basebio	£1.69M	44.36	-£9.84M	-£109.00	N/A

4basebio has a consensus target price of GBX 1,400, indicating a potential upside of 188.66%. Given 4basebio's stronger consensus rating and higher probable upside, analysts plainly believe 4basebio is more favorable than Horizon Discovery Group plc (HZD.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Horizon Discovery Group plc (HZD.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A
4basebio	N/A	-231.29%	-54.30%

In the previous week, 4basebio had 1 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 1 mentions for 4basebio and 0 mentions for Horizon Discovery Group plc (HZD.L). 4basebio's average media sentiment score of 0.75 beat Horizon Discovery Group plc (HZD.L)'s score of 0.00 indicating that 4basebio is being referred to more favorably in the news media.

Company	Overall Sentiment
Horizon Discovery Group plc (HZD.L)	Neutral
4basebio	Positive

Summary

4basebio beats Horizon Discovery Group plc (HZD.L) on 8 of the 12 factors compared between the two stocks.

How does 4basebio compare to Avacta Group?

4basebio (LON:4BB) and Avacta Group (LON:AVCT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

4basebio has a net margin of 0.00% compared to Avacta Group's net margin of -33,961.06%. 4basebio's return on equity of -231.29% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4basebio	N/A	-231.29%	-54.30%
Avacta Group	-33,961.06%	-2,929.47%	-21.80%

4basebio has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than 4basebio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4basebio	£1.69M	44.36	-£9.84M	-£109.00	N/A
Avacta Group	£113K	2,778.12	-£30.08M	-£9.66	N/A

4basebio currently has a consensus price target of GBX 1,400, suggesting a potential upside of 188.66%. Avacta Group has a consensus price target of GBX 99, suggesting a potential upside of 47.76%. Given 4basebio's higher probable upside, equities analysts clearly believe 4basebio is more favorable than Avacta Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, 4basebio and 4basebio both had 1 articles in the media. 4basebio's average media sentiment score of 0.75 beat Avacta Group's score of 0.67 indicating that 4basebio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4basebio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avacta Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

4basebio has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

0.9% of 4basebio shares are held by institutional investors. Comparatively, 3.1% of Avacta Group shares are held by institutional investors. 12.1% of 4basebio shares are held by company insiders. Comparatively, 47.7% of Avacta Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

4basebio beats Avacta Group on 7 of the 13 factors compared between the two stocks.

How does 4basebio compare to PureTech Health?

PureTech Health (LON:PRTC) and 4basebio (LON:4BB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

32.5% of PureTech Health shares are owned by institutional investors. Comparatively, 0.9% of 4basebio shares are owned by institutional investors. 13.4% of PureTech Health shares are owned by insiders. Comparatively, 12.1% of 4basebio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

4basebio has lower revenue, but higher earnings than PureTech Health. 4basebio is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	61.44	-£91.86M	-£46.00	N/A
4basebio	£1.69M	44.36	-£9.84M	-£109.00	N/A

4basebio has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. PureTech Health's return on equity of -31.98% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
4basebio	N/A	-231.29%	-54.30%

In the previous week, PureTech Health and PureTech Health both had 1 articles in the media. PureTech Health's average media sentiment score of 1.11 beat 4basebio's score of 0.75 indicating that PureTech Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
4basebio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PureTech Health presently has a consensus price target of GBX 508, indicating a potential upside of 331.97%. 4basebio has a consensus price target of GBX 1,400, indicating a potential upside of 188.66%. Given PureTech Health's higher possible upside, research analysts clearly believe PureTech Health is more favorable than 4basebio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

PureTech Health has a beta of 0.771, indicating that its share price is 23% less volatile than the broader market. Comparatively, 4basebio has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

Summary

PureTech Health beats 4basebio on 10 of the 13 factors compared between the two stocks.

How does 4basebio compare to Arix Bioscience?

4basebio (LON:4BB) and Arix Bioscience (LON:ARIX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

0.9% of 4basebio shares are held by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are held by institutional investors. 12.1% of 4basebio shares are held by insiders. Comparatively, 20.7% of Arix Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

4basebio currently has a consensus target price of GBX 1,400, suggesting a potential upside of 188.66%. Given 4basebio's stronger consensus rating and higher possible upside, equities research analysts plainly believe 4basebio is more favorable than Arix Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Arix Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Arix Bioscience has a net margin of 105.64% compared to 4basebio's net margin of 0.00%. Arix Bioscience's return on equity of 6.41% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4basebio	N/A	-231.29%	-54.30%
Arix Bioscience	105.64%	6.41%	2.18%

4basebio has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Arix Bioscience has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

In the previous week, 4basebio had 1 more articles in the media than Arix Bioscience. MarketBeat recorded 1 mentions for 4basebio and 0 mentions for Arix Bioscience. 4basebio's average media sentiment score of 0.75 beat Arix Bioscience's score of 0.00 indicating that 4basebio is being referred to more favorably in the media.

Company	Overall Sentiment
4basebio	Positive
Arix Bioscience	Neutral

Arix Bioscience has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4basebio	£1.69M	44.36	-£9.84M	-£109.00	N/A
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A

Summary

Arix Bioscience beats 4basebio on 9 of the 15 factors compared between the two stocks.

How does 4basebio compare to Circassia Group?

Circassia Group (LON:CIR) and 4basebio (LON:4BB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

4basebio has a consensus price target of GBX 1,400, suggesting a potential upside of 188.66%. Given 4basebio's stronger consensus rating and higher probable upside, analysts plainly believe 4basebio is more favorable than Circassia Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Circassia Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Circassia Group has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Circassia Group	£27.90M	0.00	N/A	£0.01	N/A
4basebio	£1.69M	44.36	-£9.84M	-£109.00	N/A

Circassia Group's return on equity of 0.00% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Circassia Group	N/A	N/A	N/A
4basebio	N/A	-231.29%	-54.30%

0.9% of 4basebio shares are held by institutional investors. 12.1% of 4basebio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, 4basebio had 1 more articles in the media than Circassia Group. MarketBeat recorded 1 mentions for 4basebio and 0 mentions for Circassia Group. 4basebio's average media sentiment score of 0.75 beat Circassia Group's score of 0.00 indicating that 4basebio is being referred to more favorably in the news media.

Company	Overall Sentiment
Circassia Group	Neutral
4basebio	Positive

Summary

4basebio beats Circassia Group on 7 of the 12 factors compared between the two stocks.

Get 4basebio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

4BB vs. The Competition

Export

Metric	4basebio	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£72.00M	£4.01B	£7.38B	£2.54B
Dividend Yield	N/A	3.64%	2.53%	6.17%
P/E Ratio	-4.45	11.62	272.60	367.57
Price / Sales	44.36	1,334.59	623.32	83,481.74
Price / Cash	16.08	105.14	78.62	27.89
Price / Book	-11.83	16.80	13.05	7.19
Net Income	-£9.84M	-£12.50M	£3.47B	£5.89B
7 Day Performance	-11.82%	3.29%	2.09%	0.30%
1 Month Performance	-6.69%	8.23%	6.63%	3.31%
1 Year Performance	-44.98%	55.05%	25.01%	22.13%

4basebio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
4BB 4basebio	2.0332 of 5 stars	GBX 485 +4.3%	GBX 1,400 +188.7%	-45.0%	£72.00M	£1.69M	N/A	101	News Coverage Gap Up
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
AVCT Avacta Group	2.4394 of 5 stars	GBX 64.63 +1.0%	GBX 99 +53.2%	+38.0%	£299.87M	£113K	N/A	120	News Coverage
PRTC PureTech Health	3.6134 of 5 stars	GBX 119.69 -2.1%	GBX 508 +324.4%	-15.2%	£289.18M	£4.66M	N/A	300
ARIX Arix Bioscience	N/A	N/A	N/A	N/A	£183.73M	£14.16M	1,290.91	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:4BB) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

4basebio (4BB) Competitors

4BB vs. HZD, AVCT, PRTC, ARIX, and CIR

How does 4basebio compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does 4basebio compare to Avacta Group?

Summary

How does 4basebio compare to PureTech Health?

Summary

How does 4basebio compare to Arix Bioscience?

Summary

How does 4basebio compare to Circassia Group?

Summary

Media Sentiment Over Time

4BB vs. The Competition

4basebio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

4basebio (4BB) Competitors

4BB vs. HZD, AVCT, PRTC, ARIX, and CIR

How does 4basebio compare to Horizon Discovery Group plc (HZD.L)?

Do institutionals & insiders believe in HZD or 4BB?

Which has higher earnings & valuation, HZD or 4BB?

Do analysts prefer HZD or 4BB?

Is HZD or 4BB more profitable?

Does the media favor HZD or 4BB?

Summary

How does 4basebio compare to Avacta Group?

Is 4BB or AVCT more profitable?

Which has preferable valuation and earnings, 4BB or AVCT?

Do analysts prefer 4BB or AVCT?

Does the media refer more to 4BB or AVCT?

Which has more volatility and risk, 4BB or AVCT?

Do insiders and institutionals hold more shares of 4BB or AVCT?

Summary

How does 4basebio compare to PureTech Health?

Do institutionals and insiders believe in PRTC or 4BB?

Which has higher valuation and earnings, PRTC or 4BB?

Is PRTC or 4BB more profitable?

Does the media favor PRTC or 4BB?

Do analysts recommend PRTC or 4BB?

Which has more risk & volatility, PRTC or 4BB?

Summary

How does 4basebio compare to Arix Bioscience?

Do insiders and institutionals hold more shares of 4BB or ARIX?

Do analysts recommend 4BB or ARIX?

Is 4BB or ARIX more profitable?

Which has more risk and volatility, 4BB or ARIX?

Does the media refer more to 4BB or ARIX?

Which has higher earnings & valuation, 4BB or ARIX?

Summary

How does 4basebio compare to Circassia Group?

Do analysts prefer CIR or 4BB?

Which has better earnings & valuation, CIR or 4BB?

Is CIR or 4BB more profitable?

Do insiders & institutionals have more ownership in CIR or 4BB?

Does the media prefer CIR or 4BB?

Summary

Media Sentiment Over Time

4BB vs. The Competition

4basebio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools